Source comparison
Loading Phase vs Maintenance Phase Dosing Protocols
The loading phase exists to rapidly elevate plasma and tissue concentrations of thymosin beta-4 above the threshold required for angiogenesis and cellular migration. Studies on TB-500 pharmacokinetics show that peak plasma concentration occurs 30–60 minutes po
This comparison does not assign a generated winner or score.
- The loading phase exists to rapidly elevate plasma and tissue concentrations of thymosin beta-4 above the threshold required for angiogenesis and cellular migration. Studies on TB-500 pharmacokinetics show that peak plasma concentration occurs 30–60 minutes post-injection, with a half-life of approximately 10–14 days depending on injection route. This means weekly injections during loading create sustained elevation, while maintenance dosing prevents concentration from dropping below the therapeutic threshold once tissue repair processes are active.
- Loading phase protocol (acute injuries): 5–10mg administered subcutaneously twice weekly for 4 weeks. Total weekly dose: 10–20mg. This phase is used for fresh injuries (less than 6 weeks old), post-surgical recovery, or severe muscle tears where rapid angiogenesis is critical. The goal is tissue saturation. Getting thymosin beta-4 into damaged tissue fast enough to prevent fibrous scar formation and initiate organized collagen deposition instead.
- Maintenance phase protocol: 2–5mg administered subcutaneously once or twice weekly for 8–12 weeks after loading. Total weekly dose: 2–10mg depending on injury severity. This phase sustains the repair processes initiated during loading. Collagen remodeling takes 8–16 weeks in tendon tissue. Stopping TB-500 after 4 weeks means repair signaling drops off before structural integrity is restored.
- Chronic injury protocol (injuries older than 12 weeks): 2.5–5mg administered subcutaneously twice weekly without a loading phase. Chronic injuries involve established scar tissue and reduced vascularity, so the focus shifts from rapid saturation to sustained low-level signaling that gradually remodels fibrotic tissue. Front-loading doesn't accelerate this process because the limiting factor is tissue turnover rate, not peptide availability.
- Subcutaneous injection into abdominal tissue provides slower, more sustained release compared to intramuscular injection near the injury site. While localized IM injection produces higher short-term concentration at the injury, systemic SC administration maintains plasma levels longer, which matters more for tissue repair than peak concentration. The peptide circulates and accumulates in injury zones through chemotactic signaling. You don't need to inject directly into a torn tendon for it to reach that tissue.